Ishares Trust · net assets $9.09B · 252 holdings as of June 30, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 89.2% · STIV: 10.8% · OTHER: 0.0% · DE: 0.0%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $742M | $791M | $984M |
| Reinvestment | $0 | $0 | $0 |
| Redemptions | $908M | $966M | $685M |
| Net realized gain (non-derivative) | $113M | $93.3M | $-100M |
| Net unrealized appreciation (non-derivative) | $-126M | $77.2M | $944M |
The three months of the reporting period, as filed; month 3 ends June 30, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Blackrock Funds Iii STIV | $1.06B | 11.66% |
| Vertex Pharmaceuticals, Inc. EC | $734M | 8.08% |
| Amgen, Inc. EC | $711M | 7.83% |
| Gilead Sciences, Inc. EC | $622M | 6.84% |
| Regeneron Pharmaceuticals, Inc. EC | $446M | 4.91% |
| Argenx Se EC | $342M | 3.76% |
| Alnylam Pharmaceuticals, Inc. EC | $284M | 3.12% |
| Natera, Inc. EC | $263M | 2.89% |
| Revolution Medicines, Inc. EC | $253M | 2.78% |
| Biogen, Inc. EC | $224M | 2.47% |
| Illumina, Inc. EC | $188M | 2.07% |
| Moderna, Inc. EC | $180M | 1.98% |
| Insmed, Inc. EC | $162M | 1.78% |
| Beone Medicines Ltd. EC | $161M | 1.77% |
| Incyte Corp. EC | $159M | 1.75% |
| United Therapeutics Corp. EC | $158M | 1.73% |
| Roivant Sciences Ltd. EC | $130M | 1.43% |
| Neurocrine Biosciences, Inc. EC | $118M | 1.30% |
| Ascendis Pharma A/s EC | $117M | 1.29% |
| Genmab A/s EC | $102M | 1.12% |
| Exelixis, Inc. EC | $93.9M | 1.03% |
| Ionis Pharmaceuticals, Inc. EC | $91.1M | 1.00% |
| Bridgebio Pharma, Inc. EC | $89.2M | 0.98% |
| Medpace Holdings, Inc. EC | $86.3M | 0.95% |
| Madrigal Pharmaceuticals, Inc. EC | $82.5M | 0.91% |
| Bio-techne Corp. EC | $78.1M | 0.86% |
| Biomarin Pharmaceutical, Inc. EC | $77.2M | 0.85% |
| Charles River Laboratories International, Inc. EC | $76.5M | 0.84% |
| Arrowhead Pharmaceuticals, Inc. EC | $76.4M | 0.84% |
| Axsome Therapeutics, Inc. EC | $74.7M | 0.82% |
| Cytokinetics, Inc. EC | $71.9M | 0.79% |
| Krystal Biotech, Inc. EC | $67.8M | 0.75% |
| Halozyme Therapeutics, Inc. EC | $65.1M | 0.72% |
| Praxis Precision Medicines, Inc. EC | $61.9M | 0.68% |
| Abivax Sa EC | $61.1M | 0.67% |
| Alkermes PLC EC | $60.5M | 0.67% |
| Biontech Se EC | $60.2M | 0.66% |
| Vaxcyte, Inc. EC | $58.2M | 0.64% |
| Kymera Therapeutics, Inc. EC | $57.8M | 0.64% |
| Apogee Therapeutics, Inc. EC | $53.6M | 0.59% |
| Protagonist Therapeutics, Inc. EC | $53M | 0.58% |
| Rhythm Pharmaceuticals, Inc. EC | $52.2M | 0.57% |
| Repligen Corp. EC | $51.6M | 0.57% |
| Spyre Therapeutics, Inc. EC | $48.6M | 0.54% |
| Bruker Corp. EC | $47.4M | 0.52% |
| Ptc Therapeutics, Inc. EC | $46.3M | 0.51% |
| Nuvalent, Inc. EC | $45.7M | 0.50% |
| Twist Bioscience Corp. EC | $43.4M | 0.48% |
| Tempus Ai, Inc. EC | $43.4M | 0.48% |
| Mirum Pharmaceuticals, Inc. EC | $41.1M | 0.45% |
| Cogent Biosciences, Inc. EC | $40.3M | 0.44% |
| Xenon Pharmaceuticals, Inc. EC | $38.8M | 0.43% |
| Scholar Rock Holding Corp. EC | $37.6M | 0.41% |
| Travere Therapeutics, Inc. EC | $36.4M | 0.40% |
| Definium Therapeutics, Inc. EC | $35M | 0.38% |
| Crispr Therapeutics Ag EC | $34.6M | 0.38% |
| Blackrock Funds Iii STIV | $34.3M | 0.38% |
| Oruka Therapeutics, Inc. EC | $34.2M | 0.38% |
| Veracyte, Inc. EC | $32.4M | 0.36% |
| 10x Genomics, Inc. EC | $30.6M | 0.34% |
Showing top 60 of 252 holdings.
Loading...
